BioMotiv
Accelerating Breakthrough Discoveries into Medicines

News

News

SapVax Achieves Technical Milestone, Raises Additional Funding, and Expands Advisory Board

SapVax, a BioMotiv portfolio company developing a suite of cancer vaccines based on novel self-adjuvanting peptide technology, has achieved a significant proof-of-principle milestone, expanded its Scientific Advisory Board, and closed a new round of equity financing to continue to advance its unique platform towards the clinic.

Read More
Nature Features Sujana’s Technology

Nature Communications has published the research of Daniel I. Simon, M.D.; Edward Plow, Ph.D.; and Yunmei Wang, Ph.D. – Founders of Sujana Biotech – which describes a novel target for thrombotic disorders that does not effect hemostasis (bleeding time).

Read More
Erin Reese